RT Journal Article
SR Electronic
T1 Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.21.20248643
DO 10.1101/2020.12.21.20248643
A1 Raches Ella
A1 Siddharth Reddy
A1 Harsh Jogdand
A1 Vamshi Sarangi
A1 Brunda Ganneru
A1 Sai Prasad
A1 Dipankar Das
A1 Dugyala Raju
A1 Usha Praturi
A1 Gajanan Sapkal
A1 Pragya Yadav
A1 Prabhakar Reddy
A1 Savita Verma
A1 Chandramani Singh
A1 Sagar Vivek Redkar
A1 Chandra Sekhar Gillurkar
A1 Jitendra Singh Kushwaha
A1 Satyajit Mohapatra
A1 Amit Bhate
A1 Sanjay Rai
A1 Samiran Panda
A1 Priya Abraham
A1 Nivedita Gupta
A1 Krishna Ella
A1 Balram Bhargava
A1 Krishna Mohan Vadrevu
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248643.abstract
AB Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg) formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, we reported findings from a phase 1 (vaccination regimen on days 0 and 14) randomised, double-blind trial on the safety and immunogenicity of three different formulations of BBV152 and one control arm containing Algel (without antigen). Two formulations were selected for the phase 2 (days 0 and 28) study. Here, we report interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152: 3 µg and 6 µg with Algel-IMDG.Methods We conducted a double-blind, randomised, multicentre, phase 2 clinical trial to evaluate the immunogenicity and safety of BBV152. A total of 380 healthy children and adults were randomised to receive two vaccine formulations (n=190 each) with 3 µg with Algel-IMDG and 6 µg with Algel-IMDG. Two intramuscular doses of vaccines were administered (four weeks apart). Participants, investigators, and laboratory staff were blinded to the treatment allocation. The primary outcome was seroconversion (≥4-fold above baseline) based on wild-type virus neutralisation (PRNT50). Secondary outcomes were reactogenicity and safety. Cell-mediated responses were evaluated. A follow-up blood draw was collected from phase 1 participants at day 104 (three months after the second dose).Findings Among 921 participants screened between Sep 7-13, 2020, 380 participants were randomised to the safety and immunogenicity population. The PRNT50 seroconversion rates of neutralising antibodies on day 56 were 92·9% (88·2, 96·2) and 98·3% (95·1, 99·6) in the 3 µg and 6 µg with Algel-IMDG groups, respectively. Higher neutralising titres (2-fold) were observed in the phase 2 study than in the phase 1 study (p<0.05). Both vaccine groups elicited more Th1 cytokines than Th2 cytokines. After two doses, the proportion (95% CI) of solicited local and systemic adverse reactions were 9.7% (6·9, 13·2) and 10.3% (7·4, 13·8) in the 3 µg and 6 µg with Algel-IMDG groups, respectively. No significant difference was observed between the groups. No serious adverse events were reported in this study. Phase 1 follow-up immunological samples at day 104 showed seroconversion in 73·5% (63·6, 81·9), 81·1% (71·4, 88·1), and 73·1% (62·9, 81·8) of individuals in the 3 µg with Algel-IMDG, 6 µg with Algel-IMDG, and 6 µg with Algel groups, respectively.Interpretation In the phase 1 trial, BBV152 produced high levels of neutralising antibodies that remained elevated in all participants three months after the second vaccination. In the phase 2 trial, BBV152 led to tolerable safety outcomes and enhanced humoral and cell-mediated immune responses. The safety profile of BBV152 is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates. The 6 µg Algel-IMDG formulation was selected for the phase 3 efficacy trial.Funding This work was supported and funded by Bharat Biotech International Limited.Clinicaltrials.gov: NCT04471519Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicaltrials.gov: NCT04471519Funding StatementThe study was funded by Bharat Biotech.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Details and individual names of the Ethics Committee members were not provided to the authors. Nizams Institute of Medical Science, Hyderabad, Telangana ECR/303/INST/AP/2013/RR-19 All India Institute of Medical Science, New DelhiECR/547/INST/DL/2014/RR-17 PGIMS, Rohtak, Haryana ECR/293/Inst/HR/2013/RR-19 All India Institute of Medical Science, PatnaECR/1387/INST/BR/2020 Redkar Hospital & Research Centre, GoaECR/902/INST/GA/2018 Jeevan Rekha Hospital, Belgaum, KarnatakaECR/1242/INST/KA/2019 Gillukar Multispecialty Hospital, NagpurECR/1374/INST/MH/2020 Prakhar Hospital, Kanpur, Uttar PradeshECR/1017/INST/UP/2017 SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu ECR/431/INST/TL/2013/RR-19All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol is provided in the Supplemental Appendix Individual participant (de-identified) data will be made available when the trial is complete upon request directed to the corresponding author, after the approval of a proposal, data can be shared through a secure online platform.